The T-DXd Revolution for Postoperative Residual Disease in HER2-Positive Breast Cancer
In this article
The strongest response against resistant cells after surgery: Trastuzumab Deruxtecan (T-DXd, Enhertu) is establishing a new standard in oncology by halving the risk of recurrence.
Patients with early-stage HER2-positive breast cancer who have viable cancer cells remaining despite preoperative (neoadjuvant) treatments are at the highest risk of recurrence. Until now, T-DM1 (Kadcyla) has guided treatment in this group. But medicine does not stand still: it aims for more, for a more lasting state of well-being. Published in the NEJM on 26 February 2026, the DESTINY-Breast05 results redraw the map of those insidious cells "left behind" through T-DXd, reducing the likelihood of recurrence to a historic level.
Biological Precision: A New Peak for ADC Technology
On the journey through HER2-positive breast cancer, what we need most to preserve the body's internal balance are smart methods that focus only on the target without harming healthy tissues. Antibody-drug conjugates (ADCs) act like "guiding molecules", delivering their chemotherapy payload directly to the target.
In the DESTINY-Breast05 study, 1635 participants were divided between two large groups. The aim was to compare the protective power of the existing standard, T-DM1, with the next-generation T-DXd (Enhertu). The results revealed a difference clear enough to enter the oncology literature.
Healing beyond the Numbers: Years Free of Disease
Data obtained after a median follow-up of 30 months demonstrate why T-DXd is a candidate to become a new standard:
- Preventing Invasive Recurrence: In the T-DXd group, 92.4% of patients were living without any recurrence at 3 years, whereas this rate remained at 83.7% with standard treatment.
- Distant Recurrence and Brain Metastasis: The study showed that the drug provides superior protection not only in the breast region but also at distant sites in the body, particularly in sensitive areas such as the brain.
Side-Effect Profile and Informed Management
Like every advanced treatment, T-DXd has its own biological cost. It is best to view this process not as a "battle", but as a process of "balance" undertaken with awareness of the side effects.
| Treatment Group | Most Common Symptoms | Critical Warning (ILD) |
|---|---|---|
| T-DXd (Enhertu) | Nausea (71%), Constipation, Low White Blood Cell Count | %9.6 (Interstitial Lung Disease) |
| T-DM1 (Kadcyla) | Elevated Liver Enzymes (50%), Low Platelet Count | %1.6 |
Looking to the Future with Confidence: A New Path to Restoration
In our story with cancer, our goal is not simply to eliminate the tumor, but to build a person's tomorrow in the healthiest and safest way. The DESTINY-Breast05 data have given us history's sharpest compass for clearing the "living remnants" left after surgery in early-stage HER2-positive breast cancer.
Reducing the risk of recurrence by more than 50% means touching the lives of tens of thousands of women. Yes, on this journey we must protect sensitive balances such as lung health; nevertheless, the immense protective shield offered by T-DXd is moving our oncology practice toward more compassionate and precise healing. We continue to honor our promise to our patients: we follow the light of science for a longer, better-quality life woven with greater awareness.
Scientific Sources
- 1. Loibl S, et al. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. N Engl J Med 2026; 394:845-857.
- 2. von Minckwitz G, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (KATHERINE Trial). NEJM 2019.
- 3. DESTINY-Breast05 ClinicalTrials.gov number: NCT04622319.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.